https://socictopen.socict.org/files/original/1127ad5e5efd78596e2d2712908d753b.pdf 5ef3b46c2d361a7e8d2097c44166f7ae Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Covid-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab) Creator An entity primarily responsible for making the resource T. V. Beketova, L. M. Blank, A. M. Lila Description An account of the resource Despite numerous publications on COVID-19, at present, conceptual thinking of the problem is only at a nascence stage. Treatment of patients with ANCA-associated systemic vasculitis (AAV) during the COVID-19 pandemic is one of the relevant issues. Management of COVID-19 in AAV patients undergoing anti-B cell therapy with rituximab (RTM) requires comprehensive reasoning. This paper presents a case report about COVID-19 in a 59-year-old female with AAV in remission, who was previously treated with RTM. COVID-19 was diagnosed one month after the last RTM administration; there were moderate bilateral pneumonia, fever, and extrapulmonary manifestations, including lesions of the gastrointestinal tract and central nervous system. Clinical outcome of COVID-19 was favorable, with no signs of respiratory failure, and CRP values did not exceed 29 mg/l. We discuss published data on RTM use during COVID-19 pandemic and the effects of B cells and their depletion on the course and outcomes of COVID-19. Our case report and available published data do not allow to consider RTM therapy as a factor associated with severe course of COVID-19 and adverse outcome. Further analysis of COVID-19 in patients with AAV and other rheumatic diseases is important. Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource covid-19, rituximab, B cells, vasculitis, ANCA Identifier An unambiguous reference to the resource within a given context 10.47360/1995-4484-2020-456-462 Source A related resource from which the described resource is derived Научно-практическая ревматология Publisher An entity responsible for making the resource available IMA-PRESS LLC Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Diseases of the musculoskeletal system